Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Envafolimab + XELOX in locally advanced colon cancer
NCT05335460Phase 2Unknown
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- May 2022
- Primary completion
- May 2023
- Modality
- Nanobodies (VHH), Monoclonal Antibodies
01
Overview
Phase 2, open-label trial of envafolimab in colon cancer, sponsored by Fujian Medical University Cancer Hospital. Primary endpoint: Tumor Regression Grade 0/1 Rate. Status: unknown.
02
Drugs
envafolimab
03
Conditions
colon cancer
Beyond the preview
Go deeper on NCT05335460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05335460.